SCT I04
Alternative Names: SCT-I04Latest Information Update: 15 Mar 2021
Price :
$50 *
At a glance
- Originator Sinocelltech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD137 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Feb 2021 Preclinical trials in Solid tumours in China (Parenteral) before February 2021 (SinoCellTech pipeline, February 2021)